Contraceptive Vaginal Ring (CVR)

ApprovedSmall molecule

PPenn State University

Contraceptive Vaginal Ring (CVR) is one of 2 small molecule programs targeting Other. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OtherActive, not recruiting

OtherApproved

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Other

#DrugCompanyPhaseTrials

Contraceptive Vaginal Ring (CVR)

PPenn State University

Approved

1 2

Combined Oral Contraceptive (COC)

PPenn State University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedActive, not recruiting

Other

NCT02367846

Clinical

Trials by Indication[1]

Other1 trial

The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology

Active, not recruiting·PPenn State University·Approved·NCT02367846·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Contraceptive Vaginal Ring (CVR). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Contraceptive Vaginal Ring (CVR) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Contraceptive Vaginal Ring (CVR). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Penn State University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPenn State University

Contraceptive Vaginal Ring (CVR)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Other1 trial

References

Drug Info

Quick Facts

Related News